Cited by 386Advanced Drug Delivery SystemsNanoparticle-Based Drug DeliveryMicroencapsulation and Drying Processes

Issues in long-term protein delivery using biodegradable microparticles

Ye, Mingli, Kim, Sungwon, Park, Kinam·2010·Journal of Controlled Release

Abstract

Recently, a variety of bioactive protein drugs have been available in large quantities as a result of advances in biotechnology. Such availability has prompted development of long-term protein delivery systems. Biodegradable microparticulate systems have been used widely for controlled release of protein drugs for days and months. The most widely used biodegradable polymer has been poly(d,l-lactic-co-glycolic acid) (PLGA). Protein-containing microparticles are usually prepared by the water/oil/water (W/O/W) double emulsion method, and variations of this method, such as solid/oil/water (S/O/W) and water/oil/oil (W/O/O), have also been used. Other methods of preparation include spray drying, ultrasonic atomization, and electrospray methods. The important factors in developing biodegradable microparticles for protein drug delivery are protein release profile (including burst release, duration of release, and extent of release), microparticle size, protein loading, encapsulation efficiency, and bioactivity of the released protein. Many studies used albumin as a model protein, and thus, the bioactivity of the release protein has not been examined. Other studies which utilized enzymes, insulin, erythropoietin, and growth factors have suggested that the right formulation to preserve bioactivity of the loaded protein drug during the processing and storage steps is important. The protein release profiles from various microparticle formulations can be classified into four distinct categories (Types A, B, C, and D). The categories are based on the magnitude of burst release, the extent of protein release, and the protein release kinetics followed by the burst release. The protein loading (i.e., the total amount of protein loaded divided by the total weight of microparticles) in various microparticles is 6.7+/-4.6%, and it ranges from 0.5% to 20.0%. Development of clinically successful long-term protein delivery systems based on biodegradable microparticles requires improvement in the drug loading efficiency, control of the initial burst release, and the ability to control the protein release kinetics.

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2010.05.011

Cites

180 of 180 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The w/o/w method is relatively simple and economic, but it can have low encapsulation efficiency or payload and a large initial burst release because organic solvent removal is slow.

    “Although this w/o/w method is a relatively simple and economic technique [9], the sometimes low encapsulation efficiency or payload as well as the huge initial burst release, because of the limited speed of removal of organic solvent, are disadvantageous [10].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ye, M., Kim, S., & Park, K.
Affiliations
Purdue University West Lafayette (US)
Corresponding author
Park, Kinam
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2010-09-01
Volume
146
Issue
2
Pages
241-260
ISSN
0168-3659 (ISSN-L)
OpenAlex
W2161765731
Cited by
386
References
180
Citations by year
2026: 8 · 2025: 11 · 2024: 14 · 2023: 18 · 2022: 20 · 2021: 16 · 2020: 14 · 2019: 31 · 2018: 24 · 2017: 28 · 2016: 29 · 2015: 34 · 2014: 43 · 2013: 37 · 2012: 30
FWCI
21.44
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Controlled Release (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute (CA129287, R01CA129287)
  • National Institute of General Medical Sciences (R01GM067044, GM067044)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Microencapsulation and Drying Processes
Keywords
protein drug delivery, biodegradable microparticles, PLGA, controlled release, protein release kinetics, burst release, encapsulation efficiency, protein bioactivity, albumin, insulin, growth factors, microparticle size, drug loading
MeSH terms
Polylactic Acid-Polyglycolic Acid Copolymer, Animals, Delayed-Action Preparations, Drug Compounding, Humans, Polyglycolic Acid, Proteins, Recombinant Proteins, Lactic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review